ARCT-2303 / Arcturus Therap, CSL Behring - LARVOL DELTA

Immunogenicity and Safety Study of Self-amplifying MRNA COVID-19 Vaccine Administered with Influenza Vaccines in Adults (clinicaltrials.gov) - P3 | N=1499 | Completed | Sponsor: Arcturus Therapeutics, Inc. | Active, not recruiting ➔ Completed

Trial completion • Infectious Disease • Influenza • Novel Coronavirus Disease • Respiratory Diseases

Immunogenicity and Safety Study of Self-amplifying mRNA COVID-19 Vaccine Administered With Influenza Vaccines in Adults (clinicaltrials.gov) - P3 | N=1680 | Active, not recruiting | Sponsor: Arcturus Therapeutics, Inc. | Recruiting ➔ Active, not recruiting

Enrollment closed • Infectious Disease • Influenza • Novel Coronavirus Disease • Respiratory Diseases

Immunogenicity and Safety Study of Self-amplifying mRNA COVID-19 Vaccine Administered With Influenza Vaccines in Adults (clinicaltrials.gov) - P3 | N=1680 | Recruiting | Sponsor: Arcturus Therapeutics, Inc. | Not yet recruiting ➔ Recruiting

Enrollment open • Infectious Disease • Influenza • Novel Coronavirus Disease • Respiratory Diseases

Immunogenicity and Safety Study of Self-amplifying mRNA COVID-19 Vaccine Administered With Influenza Vaccines in Adults (clinicaltrials.gov) - P3 | N=1680 | Not yet recruiting | Sponsor: Arcturus Therapeutics, Inc.

New P3 trial • Infectious Disease • Influenza • Novel Coronavirus Disease • Respiratory Diseases